Stephen Hanauer to Placebos
This is a "connection" page, showing publications Stephen Hanauer has written about Placebos.
Connection Strength
0.813
-
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147.
Score: 0.154
-
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90.
Score: 0.117
-
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
Score: 0.100
-
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007 May; 23(5):1033-43.
Score: 0.070
-
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802.
Score: 0.069
-
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
Score: 0.068
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591.
Score: 0.064
-
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
Score: 0.063
-
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99.
Score: 0.048
-
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
Score: 0.021
-
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
Score: 0.021
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
Score: 0.017